Huadong Pharma announced a $662 million agreement to develop two Kiniksa Pharma anti-inflammatory drug candidates in southeast Asia (ex-Japan). Huadong will pay $22 million and be responsible for up to $640 million in milestones, plus royalties.

Exelixis, Inc. broke away with a major move on Monday, and followed up on Tuesday, popping 98 cents, or 4%, to 24.56, with a session and multi-week high of 25.13, on 7.7 million shares traded.